Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 8Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Vomiting 4Nausea 3Sezary Syndrome 1Pruritus 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Brenner Tumor 1Breast Neoplasms 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Aprepitant × Clear all
NCT00869973 2013-01-23

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients

S. Maria Hospital, Terni

Phase 3 Terminated
580 enrolled
Breast

Breast Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡